Literature DB >> 18835754

A high-performance liquid chromatography-tandem mass spectrometry method for the clinical combination study of carboplatin and anti-tumor agent eribulin mesylate (E7389) in human plasma.

Christopher Desjardins1, Phil Saxton, Sharon X Lu, Xiaofang Li, Christopher Rowbottom, Y Nancy Wong.   

Abstract

An LC/MS/MS method was developed to quantify carboplatin and eribulin mesylate (E7389) in human plasma and urine. For carboplatin, sample clean-up by protein precipitation and supernatant injection into a Waters Spherisorb((R)) S5 SCX column was used. Liquid-phase extraction and reverse-phase chromatography on a Polaris C18 column were used for eribulin. Quantitation involved LC/MS/MS with positive electrospray ionization. Accuracy, precision, linearity, range, specificity, recovery and stability were also evaluated. Both compounds were stable in human plasma (>or=80 days at -80 degrees C), at room temperature (>or=4h), following three freeze-thaw cycles and in 50/50 methanol/H(2)O (<4 degrees C for >or=252 days).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18835754     DOI: 10.1016/j.jchromb.2008.09.013

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  8 in total

1.  Sustained Accumulation of Microtubule-Binding Chemotherapy Drugs in the Peripheral Nervous System: Correlations with Time Course and Neurotoxic Severity.

Authors:  Krystyna M Wozniak; James J Vornov; Ying Wu; Kenichi Nomoto; Bruce A Littlefield; Christopher DesJardins; Yanke Yu; George Lai; Larisa Reyderman; Nancy Wong; Barbara S Slusher
Journal:  Cancer Res       Date:  2016-04-13       Impact factor: 12.701

2.  Peripheral Neuropathy Induced by Microtubule-Targeted Chemotherapies: Insights into Acute Injury and Long-term Recovery.

Authors:  Krystyna M Wozniak; James J Vornov; Ying Wu; Ying Liu; Valentina A Carozzi; Virginia Rodriguez-Menendez; Elisa Ballarini; Paola Alberti; Eleonora Pozzi; Sara Semperboni; Brett M Cook; Bruce A Littlefield; Kenichi Nomoto; Krista Condon; Sean Eckley; Christopher DesJardins; Leslie Wilson; Mary A Jordan; Stuart C Feinstein; Guido Cavaletti; Michael Polydefkis; Barbara S Slusher
Journal:  Cancer Res       Date:  2017-11-30       Impact factor: 12.701

3.  Eribulin mesylate in patients with refractory cancers: a Phase I study.

Authors:  Toru Mukohara; Shunji Nagai; Hirofumi Mukai; Masayuki Namiki; Hironobu Minami
Journal:  Invest New Drugs       Date:  2011-09-02       Impact factor: 3.850

4.  Eribulin shows high concentration and long retention in xenograft tumor tissues.

Authors:  Michiko Sugawara; Krista Condon; Earvin Liang; Christopher DesJardins; Edgar Schuck; Kazutomi Kusano; W George Lai
Journal:  Cancer Chemother Pharmacol       Date:  2017-06-29       Impact factor: 3.333

5.  Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.

Authors:  T R Jeffry Evans; Emma Dean; L Rhoda Molife; Juanita Lopez; Malcolm Ranson; Fatima El-Khouly; Ishtiaq Zubairi; Claudio Savulsky; Larisa Reyderman; Yan Jia; Lorna Sweeting; Alastair Greystoke; Jorge Barriuso; Rebecca Kristeleit
Journal:  Br J Cancer       Date:  2019-01-25       Impact factor: 7.640

6.  A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.

Authors:  Chris Twelves; Alan Anthoney; Claudio I Savulsky; Matthew Guo; Larisa Reyderman; Nicola Cresti; Vladimir Semiglazov; Constanta Timcheva; Ishtiaq Zubairi; Rosemary Morrison; Ruth Plummer; T R Jeffry Evans
Journal:  Br J Cancer       Date:  2019-02-20       Impact factor: 7.640

7.  Comparative Pharmacokinetics and Allometric Scaling of Carboplatin in Different Avian Species.

Authors:  Gunther Antonissen; Mathias Devreese; Siegrid De Baere; Tom Hellebuyck; Isabel Van de Maele; Lieze Rouffaer; Hendrickus J J Stemkens; Patrick De Backer; An Martel; Siska Croubels
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

Review 8.  Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment.

Authors:  Lotte van Andel; Hilde Rosing; Jan Hm Schellens; Jos H Beijnen
Journal:  Mar Drugs       Date:  2018-07-23       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.